Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SK10 in Healthy Adults
NCT06026397Phase 1Completed
- Sponsor
- Zhiyi Pharmaceutics
- Start
- Aug 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SK10 in diarrhea (3 cohorts), sponsored by Zhiyi Pharmaceutics. Primary endpoints: Treatment-Emergent Adverse Events and Clinically relevant changes from baseline electrocardiogram parameters. Started Aug 2023; status: completed.
02
Drugs
SK10
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT06026397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026397.